Letter to the FDA on Heparin Supply Chain Vulnerabilities

House Committee on Energy and Commerce · February 2, 2018

A bipartisan Congressional investigation into inconsistencies and risks in the U.S. heparin supply chain — highlighting the fragility of single-source dependency on animal-derived manufacturing.